Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term evaluation of posterior juxtascleral anecortave acetate in subfoveal exudative age-related macular degeneration
2005-000086-19Phase 3Terminated
- Sponsor
- Alcon Inc.
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anecortave in age-related macular degeneration (AMD), sponsored by Alcon Inc. Primary endpoints: Percentage of patients maintaining positive visual acuity outcome and Mean change from baseline in logMAR visual acuity score. Started May 2005; status: terminated.
02
Drugs
anecortave
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2005-000086-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000086-19.